Patents by Inventor Meiji ITAKURA

Meiji ITAKURA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for predicting prognosis of patient with cancer or inflammatory disease
    Patent number: 11193172
    Abstract: Novel means that enables prediction of prognosis of a patient with cancer or inflammatory disease is disclosed. In the method for prediction of prognosis of a patient with cancer or inflammatory disease according to the present invention, the expression level of the FROUNT gene in a sample collected from the patient is measured. Since FROUNT is a poor prognostic factor, the lower the expression level of the FROUNT gene is, the better the prognosis in the patient is predicted to be. Or, the expression level of the CC chemokine receptor/ligand gene in a sample collected from the patient is measured. Since the CC chemokine receptor/ligand gene such as CCR2 or CCR5 is a good prognostic factor, the higher the expression level of the CC chemokine receptor/ligand gene is, the better the prognosis in the patient is predicted to be.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: December 7, 2021
    Assignee: TOKYO UNIVERSITY OF SCIENCE FOUNDATION
    Inventors: Yuya Terashima, Kouji Matsushima, Etsuko Toda, Mikiya Otsuji, Meiji Itakura
  • METHOD FOR PREDICTING PROGNOSIS OF PATIENT WITH CANCER OR INFLAMMATORY DISEASE
    Publication number: 20180237860
    Abstract: Novel means that enables prediction of prognosis of a patient with cancer or inflammatory disease is disclosed. In the method for prediction of prognosis of a patient with cancer or inflammatory disease according to the present invention, the expression level of the FROUNT gene in a sample collected from the patient is measured. Since FROUNT is a poor prognostic factor, the lower the expression level of the FROUNT gene is, the better the prognosis in the patient is predicted to be. Or, the expression level of the CC chemokine receptor/ligand gene in a sample collected from the patient is measured. Since the CC chemokine receptor/ligand gene such as CCR2 or CCR5 is a good prognostic factor, the higher the expression level of the CC chemokine receptor/ligand gene is, the better the prognosis in the patient is predicted to be.
    Type: Application
    Filed: January 8, 2016
    Publication date: August 23, 2018
    Applicants: The University of Tokyo, CHIBA PREFECTURE
    Inventors: Yuya TERASHIMA, Kouji MATSUSHIMA, Etsuko TODA, Mikiya OTSUJI, Meiji ITAKURA